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Background: Tardive dyskinesia is a debilitating, intractable, hyperkinetic movement disorder which contributes to 
an increase in psychiatric morbidity. Reduced function CYP2D6 alleles have been associated with tardive dyskinesia 
pathogenesis amongst Caucasians and Asians, with CYP2D*4 and *6 and CYP2D6*10 being implicated in these races 
respectively. No similar study has been successfully conducted in black Africans.  
Objective: To determine the relationship between tardive dyskinesia and CYP2D6*17 (the major reduced function 
CYP2D6 allele in Africans). 
Methodology: Abnormal Involuntary Movements Scale (AIMS) scoring and CYP2D6 genotyping were carried out on 
psychiatric patients exposed to typical antipsychotic medications in an unmatched case control study. A case of 
tardive dyskinesia was defined as a patient with an AIMS score ≥ 2 in two body areas OR ≥ 3 in one body area 
Results: A total of 18 cases and 32 controls made up the study sample.The sample’s mean age was 36.9±12.0 years 
with median treatment duration of 7.0 years (range: 0.25 to 38 years). Multiple logistic regression revealed no 
significant association between tardive dyskinesia and CYP2D6*17 (OR=0.252; 95% CI: 0.038 to 1.647; p=0.150). 
However, use of chlorpromazine (OR=5.754; 95% CI: 1.024 to 32.328; p=0.047) and age at treatment initiation 
(OR=1.146; 95% CI: 1.021 to 1.287; p=0.021) were independent predictors of tardive dyskinesia.  
Discussion: These findings suggest that there is no association between CYP2D6*17and tardive dyskinesia in African 
psychotic patients on typical antipsychotics. However, more studies with larger sample sizes are required to provide 
more definitive conclusions regarding the nature of the relationship between CYP2D6*17 and tardive dyskinesia. 
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1. Introduction 
Tardive dyskinesia (TD) is a debilitating, intractable 
hyperkinetic movement disorder characterised by 
involuntary, repetitive, purposeless choreoathetotic 
movements. It is a serious iatrogenic adverse effect of 
dopamine receptor blocking drugs, chiefly antipsychotic 
medications (Waln & Jankovic, 2013). It can also occur 
spontaneously in some disorders such as schizophrenia 
(Ayehu et al, 2014). The condition classically presents 
as oro-facial movements, but other presentations have 
been noted including tardive akathisia, dystonia, tics or 
chorea (Waln & Jankovic, 2013). The annual incidence 
of TD in a cohort of mostly Afro-Caribbean patients with 
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a mean antipsychotic exposure of 18 years was 10.2% 
(van Harten et al, 2006). In black African or African-
American races, the risk of developing TD is up to twice 
that in Caucasians (Glazer et al, 1994). This disease has 
also been positively correlated with increasing age, 
duration of high potency neuroleptic use, neuroleptic 
dose, being non-white and type of antipsychotic drug 
(Jeste et al, 1995; Morgenstern & Glazer, 1993). Atypical 
antipsychotics have a better risk profile for causing TD 
compared to typical antipsychotics (Correll et al, 2004). 
The risk for TD is also increased by carrying the 
following genes: Dopamine Receptor D2 
(DRD2 Taq1A), Dopamine Receptor D3 
(DRD3Ser9Gly), Manganese Superoxide Dismutase 
Ala9Val (MnSOD Ala9Val) and certain Cytochrome 
P4502D6 (CYP2D6) variants (Lee & Kang, 
2011). Growing evidence suggests that different 
CYP2D6 alleles with reduced or null functioning 
phenotypes are associated with TD across different 
ethnic groups (Patsopoulos et al, 2005). These CYP2D6 
alleles also vary in their distribution across different 
ethnicities (Bradford, 2002; Sistonen et al, 2007). In 
Asian populations exposed to antipsychotic 
medications, CYP2D6*10 has been positively correlated 
to the occurrence of TD while CYP2D6*4 and CYP2D6*5 
variants in Caucasians has been reported to be 
associated with TD (Kapitany et al, 1998; Liou et al, 
2004; Nikoloff et al, 2002). These studies have shown a 
relationship between the most prevalent reduced 
function CYP2D6 variants and TD in Caucasians and 
Asians.  However, no similar relationship between TD 
and CYP2D6*17 has been shown  in black psychiatric 
patients receiving typical antipsychotics.CYP2D6*17 is 
the most prevalent reduced functionCYP2D6variant in 
blacks with a frequency of 12.2% in the Sub-Saharan 
black population (Oluka et al, 2014; Sistonen et al, 
2007). Determination of the nature of the relationship 
between specific genotypes of CYP2D6 may aid in the 
development of more personalised prescribing 
strategies which can minimize the risk of 
extrapyramidal adverse effects in susceptible patients. 
In addition, typical antipsychotics are cheaper and 
readily available in resource poor settings and 
personalised therapy will be more cost-effective 
(Rosenheck, 2007). Moreover, treatment with typical 
antipsychotics also avoids the serious adverse effects 
such as the metabolic syndrome, weight gain and raised 
triglycerides resultant from use of atypical 
antipsychotics (Gautam & Meena, 2011; Osser et al, 
1999). 
The aim of this study was to determine whether there is 
an association between the CYP2D6*17 allele and TD in 
black psychotic patients exposed to typical 
antipsychotic medications. We hypothesised that there 
is an increased risk of developing TD in patients 
exposed to typical antipsychotics and carrying the 
CYP2D6*17 allele(s). To test this hypothesis we carried 
out an unmatched case-control study in psychotic 
patients being managed at two major referral hospitals. 
2. Methods 
2.1 Study design 
An unmatched 1:2 case-control study was carried out 
with participants selected from the two major 
psychiatric referral hospitals in Zimbabwe. All 
consenting cases presenting to the outpatients clinic 
during the period from the 14th of August to the 4th of 
November 2013 were recruited into the study. The 
Abnormal Involuntary Movements Scale (AIMS) (US 
Department of Health, Education and Welfare, 1974) 
and the Schooler-Kane criteria were used in the 
identification of patients with probable TD. A case of TD 
was defined as a patient with an AIMS score ≥ 2 in two 
body areas OR ≥ 3 in one body area (Schooler & Kane, 
1982).  Systematic random sampling was done with 
every 10th patient in a consultation queue enrolled as a 
study control participant. A control was defined as any 
psychotic patient without clinical features of TD and not 
meeting the Schooler and Kane case definition criteria.  
All participants had received typical antipsychotics for 
at least three months. Two psychiatry residents 
collected demographic and other patient characteristics. 
The AIMS score was then determined through use of the 
AIMS score questionnaire. Thereafter, 5 ml of blood 
were drawn from each participant, labeled with their 
study ID and sent to the laboratory for storage and 
subsequent genotyping. We included stable, psychiatric 
outpatients exposed to typical antipsychotic therapy for 
at least three months. Patients below 18 years of age 
were excluded from the study. 
2.2 Sample processing 
Every effort was made to avoid contamination with 
extraneous DNA by strictly following good polymerase 
chain reaction (PCR) protocols and procedures. The 
work setup was thoroughly cleaned, with purification, 
amplification and analysis areas kept separate. DNA 
extraction was done using the QIAamp DNA Mini kit 
(Qiagen, CA), according to the manufacturer’s manual 
from blood collected in EDTA tubes. Taqman® 
genotyping assays (Life Technologies, USA) were used 
for allelic discrimination of CYP2D6*17 (assay 
identification number C_2222771_40) for the SNP 
1023C>T. The total reaction volume was 25 μl 
comprising 2x Taqman® PCR master-mix, 20x drug 
metabolizing genotyping assay mix and genomic DNA. 
The PCR reaction was carried out using the Applied 
Biosystems 7500 Real Time PCR machine. The reaction 
consisted of 50°C denaturation for 2 minutes and 50 
cycles with 95°C for 10 minutes and a final step of 92°C 
for 15 seconds. The participants were then labeled as 
heterozygous, hemizygous or homozygous for 
CYP2D6*17. 
2.3 Data analysis 
Patient characteristics’ data were compared between 
the cases and the controls using the independent 
sample t-test and the chi-square test for continuous and 
categorical variables, respectively. For non-normally 
distributed variables, the Mann-Whitney test was used 
in place of the independent sample t-test. Logistic 
regression was used to determine the association of the 
alleles with tardive dyskinesia, after controlling for 
covariates. The Hardy-Weinberg equilibrium was tested 
using the Chi-square goodness-of-fit test.  
All the statistical analyses were done using the 
Statistical Package for Social Sciences Version 17.0 
(Chicago, USA).  
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2.4 Ethical consideration 
The study was approved by the following institutional 
review boards: the Joint Research Ethics Committee 
(University of Zimbabwe and Parirenyatwa Hospital), 
Harare Central Hospital and the Medical Research 
Council of Zimbabwe (MRCZ reference number: 
MRCZ/B/562). The participants’ caregivers gave 
voluntary informed assent for inclusion into the study. 
The participants’ identities were then coded, creating a 
study ID. No personal identifiers were collected during 
the study.  
3.  Results 
A total of 52 patients out of 59 approached (88.1% 
response rate) participated in the study. Of these, 
genotyping for CYP2D6*17 was successful in 50 
participants. The results reported here are based on 
these 50 patients (18 cases and 32 controls).  Table 1 
shows the demographic and clinical characteristics of 
the patients in the study. The mean age of the patients 
was 36.9±12.0 years and the majority were female 
(56.0%). The median duration of treatment was 7.0 
years (range: 0.25 to 38 years).  
 Table 1: Demographic and clinical characteristics of cases and controls 
Patient characteristic 
Total 
(N = 50) 
Cases 
(n = 18) 
Controls 
(n = 32) 
Intergroup comparison 
p value 
Gender 
Male 
Female 
 
22 (44.0%) 
28 (56.0%) 
 
9 (50.0%) 
9 (50.0%) 
 
13 (40.6%) 
19 (59.4%) 
 
0.522‡ 
Current age/years (mean ± sd) 36.88 ± 12.04 44.94 ± 13.47 32.34 ± 8.40 0.001† 
Treatment duration/years 
(mean ± sd)                 
9,71 ± 9.11 12.78 ± 10.75 7.86 ± 7.69 0.085ɸ 
Age at drug initiation/years 
(mean ± sd)    
27.00 ± 8.97 31.61 ± 8.05 24.41 ± 8.51 0.005† 
Benzhexol exposure status 
Exposed    
Not exposed                                                                                         
 
39 (78.0%) 
11 (22.0%)
 
18 (100%) 
0 
 
21(65.6%) 
11 (34.4%) 
 
0.001‡‡ 
CPZ exposure status§ 
Exposed    
Not exposed                                                                                         
 
24 (48.0%) 
26 (52.0%)
 
15 (83.3%) 
3 (17.7%) 
 
9 (71.9%) 
23(28.1%) 
 
<0.0001‡‡ 
FD exposure status§ 
Exposed    
Not exposed   
 
35 (70.0%) 
15 (30.0%) 
 
14 (77.8%) 
4 (22.2%) 
 
21 (65.6%) 
11 (34.3%) 
 
0.0361‡‡ 
 
Haloperidol exposure status§ 
Exposed    
Not exposed   
 
39 (78.0%) 
11 (22.0%) 
 
15 (83.3%) 
3 (16.7%) 
 
24 (75.0%) 
8 (25.0%) 
 
0.488‡‡ 
 
CYP2D6*17 allele 
Yes 
No 
 
17 (34.0%) 
33 (66.0%) 
 
4 (22.2%) 
14 (77.8%) 
 
13 (40.6%) 
19 (59.4%) 
 
0.187‡‡ 
 
 
The majority of the patients were on haloperidol 
(78.0%), benzhexol (78.0%), and fluphenazine 
decanoate (70.0%). Less than half of the patients were 
on chlorpromazine (48.0%). Table 2 shows results of 
multivariate logistic regression. There was no 
significant association between TD and CYP2D6*17 
(OR=0.252; 95% CI: 0.038 to 1.647; p=0.150), after 
controlling for covariates. A similar observation was 
seen with duration on antipsychotics (p=0.105), 
fluphenazine decanoate (p=0.598) and gender 
(p=0.646). However, use of chlorpromazine (OR=5.754; 
95% CI: 1.024 to 32.328; p=0.047) and age at treatment 
initiation (OR=1.146; 95% CI: 1.021 to 1.287; p=0.021) 
were independent predictors of tardive dyskinesia.  
Table 3 shows the distribution of the CYP2D6*17 
genotype profiles according to cases and controls. The 
frequencies suggest that the genotypes were not in 
Hardy-Weinberg equilibrium. The frequency of the 
CYP2D6*17 allele was 22.0%. 
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Table 2: Predictors of developing tardive dyskinesia 
Predictor variable  
Wald Chi 
square 
P value Odds Ratio 
95% C.I. for odds ratio 
Lower Upper 
CPZ 3.948 0.047 5.754 1.024 32.328 
Duration  2.622 0.105 1.091 0.982 1.211 
Age at drug initiation 5.339 0.021 1.146 1.021 1.287 
Haloperidol 0.115 0.734 1.412 0.193 10.336 
FD 0.278 0.598 1.720 0.229 12.920 
Gender  0.211 0.646 1.473 0.282 7.698 
CYP2D6*17 2.072 0.150 0.252 0.038 1.647 
 
 
 Table 3: Comparison of CYP2D6*17 genotype profiles between cases and controls 
 Participants Frequency 
Case Control Total observed *H-W freq 
Genotypes ww 14(13.35) 19 (17.26) 33 (30.42) 60.84% 
mw 3 (4.31) 9 (12.48) 12 (17.16) 34.32% 
mm 1 (0.35) 4 (2.26) 5 (2.42) 4.84% 
Total 18 (13.01) 32 (29.99) 50 (44.95)  
*HWE calculation: ᵡ2            1.66 2.49 4.52  
*P value                            0.198 0.114 0.033  
*Allele freq   m 78.00%  
w 22.00%  
 
4. Discussion 
In the present case control study, we found no 
association between TD and CY2D6*17 – the major 
reduced function CYP2D6 allele in a black African 
population. These findings are supported by those of 
Lohmann et al. where the reduced function CYP2D6 
genotype did not have any influence on the 
development of TD in Caucasian patients (Lohmann et 
al, 2002). However, the findings are in contrast to those 
reported by Kapitany et al. where Caucasian patients 
heterozygous to CYP2D6 reduced function mutations 
were more susceptible to TD than those without these 
mutations (Kapitany et al, 1998).Similarly, a recent 
study observed, that the number of functional CYP2D6 
genes was positively associated with an increased risk 
of TD in an English Caucasian population exposed to 
typical antipsychotics (Koola et al, 2014). 
The inconsistent association results are possibly due to 
the differences in the sample sizes, study design, the 
primary psychiatric diagnosis, participant ethnic group 
investigated and heterogeneous inclusion criteria used 
(Lee & Kang, 2011). Interactions between certain 
genetic loci and factors such as inflammatory cytokines 
and growth hormone, which influence CYP450 enzyme 
expression, may further explain the inconsistent 
pharmacogenetic association results (Dhir et al, 2006; 
Koola et al, 2014).   
Furthermore, it would appear that extensive 
metabolism and not necessarily poor metaboliser status 
increases TD susceptibility (Koola et al, 2014). 
Previously and in this study, efforts have been on 
defining a relationship between the reduced function 
alleles and TD, but it appears carrying functional alleles 
is more likely to have a causal association with TD. The 
reasons as stated by Koola et al. could be due toCYP2D6 
generated neurotoxic metabolites such as haloperidol 
pyridinium– the (haloperidol) pyridinium hypothesis 
(Koola et al, 2014; Ulrich & Genz, 2005). However, at 
higher haloperidol doses (> 20 mg daily), CYP3A4 may 
be enzyme responsible for haloperidol pyridinium 
production (Roh et al, 2001; Usuki et al, 1996).   The 
major question still remains on the pathogenetic 
mechanism of TD development and its association with 
other typical antipsychotics. 
The major limitation of the present study was the small 
sample size obtained. In addition we could not 
determine the exact antipsychotic doses and duration of 
exposure to each medication beyond the three months. 
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These factors were not factored in the design and 
analysis of the study. However, this study encourages 
further examination of the relationship between 
CYP2D6 and TD in black psychotic patients receiving 
typical antipsychotic medications. This could be done 
through a prospective well-designed study exploring 
the effects of polymorphic interactions, HIV, alcohol, 
smoking, CYP2D6 metabolites and P450 enzyme 
expression levels. Steady state levels of haloperidol 
pyridinium could be included as this metabolite is a 
known neurotoxin and its presence is associated with 
TD – the (haloperidol) pyridinium hypothesis (Ulrich & 
Genz, 2005). 
5. Conclusion 
In conclusion, this study failed to find an association 
between CYP2D6*17 and tardive dyskinesia in African 
psychotic patients on typical antipsychotics. However,  
more studies with larger sample sizes are required to 
provide more definitive conclusions regarding the 
nature of the relationship between CYP2D6*17 and 
tardive dyskinesia Coupled with plasma level 
antipsychotic level determination, this could help 
elucidate the pathogenesis of this disease. In turn, this 
will further the formulation of prescription algorithms 
for the safe use of typical antipsychotics allowing for 
personalised therapy. Through this strategy, cost–
effective typical antipsychotic medicines such as 
haloperidol can then be safely used in resource-poor, 
underfunded psychiatric services. 
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